Protalix BioTherapeutics CEO to Speak at Major Investor Forum

Protalix BioTherapeutics at the Investor Forum

Protalix BioTherapeutics, Inc. (NYSE American: PLX) is a leading biopharmaceutical company renowned for its innovative approach to developing therapeutic proteins. With a core focus on recombinant proteins produced through its ProCellEx plant cell-based expression system, Protalix is committed to advancing healthcare solutions. This September, the company is set to participate in a notable investor forum, providing them a platform to share their advancements directly with the investment community.

Event Details

The presentation will be delivered by Dror Bashan, Protalix's President and CEO, at the upcoming Life Sciences Investor Forum. This engaging online event will take place live, allowing for real-time questions from attendees. The scheduled time for this presentation is 12:00 p.m. Eastern Daylight Time (EDT) on September 19. Moreover, for those who cannot attend in real-time, an archived webcast will be accessible following the event.

This interactive platform aims to foster an environment where investors can engage directly with company representatives, ensuring transparency and open communication. Protalix encourages interested parties to pre-register and check their online systems to enhance their participation experience during the event.

Innovations from Protalix BioTherapeutics

Protalix's commitment to developing cutting-edge therapies has made them a pioneering force in the biopharmaceutical sector. Their establishment as the first company to receive U.S. Food and Drug Administration (FDA) approval for a protein produced via a plant cell-based system underscores their innovative methods in recombinant protein production.

Key Products and Partnerships

One of Protalix's primary products is taliglucerase alfa, originally designed for the treatment of Gaucher disease. This product has been significantly developed in collaboration with Pfizer Inc., which holds worldwide rights for its commercialization, except in Brazil where Protalix retains full control. Their latest innovation, Elfabrio, obtained FDA and European Medicines Agency approval in May 2023, marking a significant milestone for Protalix.

Protalix is also engaged in a partnership with Chiesi Farmaceutici S.p.A. for the global commercialization of Elfabrio. With a rich pipeline, Protalix is actively working on various products, including PRX-115, a recombinant PEGylated uricase aimed at treating uncontrolled gout, and PRX-119, which targets NETs-related diseases.

Virtual Investor Conferences Overview

Virtual Investor Conferences (VIC) plays a pivotal role in connecting publicly traded companies with a global network of investors. It provides an interactive forum for engaging presentations and discussions that replicate the traditional investor conference experience while enhancing accessibility through online platforms.

VIC has transformed investment communication, allowing companies like Protalix to not only present their findings but also to facilitate meaningful dialogue with investors through targeted one-on-one meetings and real-time questions.

Engaging with Investors

The focus of such investor events extends beyond mere presentations. They offer companies like Protalix an opportunity to expand their reach and effectively communicate their innovations and advancements. With the growing importance of transparency in healthcare, such engagement is vital for building investor trust and confidence.

As they continue to navigate the biopharmaceutical landscape, Protalix BioTherapeutics remains committed to its mission of improving patient outcomes through novel therapies backed by robust data and scientific credibility.

Investor Relations Contact

If you have any inquiries regarding Protalix BioTherapeutics or the upcoming investor forum, Mike Moyer, Managing Director at LifeSci Advisors, is available for further communication. You can reach him at +1-617-308-4306 or via email.

Frequently Asked Questions

What is Protalix BioTherapeutics known for?

Protalix BioTherapeutics is recognized for developing recombinant therapeutic proteins using its unique plant cell-based expression system.

Who will represent Protalix at the investor forum?

Dror Bashan, the President and CEO of Protalix, will represent the company and deliver the presentation.

What is the significance of the investor forum?

The forum allows Protalix to engage directly with investors, showcasing their innovations and addressing questions in real-time.

Where can I find more information about Protalix?

Further details about Protalix’s products and initiatives can be found on their official website or via their investor relations contact.

How can I participate in the investor forum?

You can participate by pre-registering for the event and preparing for a seamless online experience.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.